EAST NORRITON, Pa., June 12 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, announced today that the results of a preclinical research study conducted with its Neo-Bladder Augment(R) will be featured in the July issue of the Journal of Urology, Vol. 180. The paper, “Early Cellular and Stromal Responses in Regeneration Versus Repair of a Mammalian Bladder Using Autologous Cell and Biodegradable Scaffold Technologies,” was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., Belinda J. Wagner, Ph.D. and Timothy A. Bertram, D.V.M., Ph.D.
Key findings of the preclinical trial -- in which either a Tengion Neo-Bladder Augment or a biodegradable mesh scaffold alone was surgically implanted following partial, trigone-sparing cystectomy and both groups were evaluated clinically at one, three, six and nine months -- show that the Tengion Neo-Bladder Augment restored baseline urodynamics as early as six months after implantation and led to a structurally and functionally complete regenerated bladder wall as early as nine months. In contrast, scaffold implants alone failed to return to urodynamic baseline by the study termination and failed to regenerate a complete bladder wall.
“We continue to see great promise in our neo-bladder research programs and these latest data underscore the potential of Tengion’s Autologous Organ Regeneration Platform(TM) to provide a neo-organ that allows the body to regenerate a functional organ,” said Dr. Bertram, Senior Vice President, Science and Technology of Tengion. “We are looking forward to formally sharing these findings with our peers and continuing to develop our Neo-Bladder Augment and the Tengion Neo-Bladder Replacement(R) to meet the critical patient needs that exist today.”
About Tengion
Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient’s own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body’s innate ability to regenerate. Tengion’s product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.
CONTACT: Gary Sender of Tengion, Inc., +1-267-960-4802 or Keri Mattox of
Pure Communications, +1-215-791-0105
Web site: http://www.tengion.com/
